Ten analysts covered ResMed (RMD) in September. Four analysts gave ResMed stock a “buy” or higher rating, five analysts gave it a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for ResMed stock is 2.6, and its target price is $104.69.
ResMed (RMD) stock has been on an upward trajectory in 2018. Its stock has risen from $85.53 on January 2 to its current level of ~$114.00 in September.
ResMed’s enterprise value is $16.58 billion, and its enterprise-value-to-revenue ratio is 7.09. Its price-to-sales ratio is 6.99, and its price-to-book ratio is 7.94. ResMed is trading at a forward price-to-earnings multiple of 27.81x.
RMD’s current ratio, which measures how effectively a company can meet its short-term obligations, stands at 2.10. The current ratios of its peers Agilent Technologies, Stryker, and Thermo Fisher Scientific stand at 3.6, 1.8, and 1.6, respectively.
ResMed’s long-term debt-to-equity ratio stands at 0.13. The long-term debt-to-equity ratios of Agilent Technologies, Stryker, and Thermo Fisher Scientific stand at 0.39, 0.63, and 0.67, respectively, indicating that ResMed has lower leverage than its peers.